OncoSec Medical Inc (ONCSQ)

[guti]

The abstract, IL-15 Augments Antibody-Dependent Cell-Mediated Cytotoxicity of Anticancer Monoclonal Antibodies, will be presented by the Senior Investigator of  Head, Cytokine Immunology and Immunotherapy Section at the Center for Cancer Research for the  National Cancer Institute, who will have a keynote presentation at PEGS Boston on April 2016. Dr.  Waldmann will be speaking on a recent study sponsored by the NCI that focused on Cytokine IL-15, the interleukin Oncosec will soon introduce to the ImmunoPulse platform.

In clinical trials IL-15 increased the number of activated NK cells and monocytes in patients with metastatic malignancy. In a preclinical syngeneic tumor model IL-15 dramatically increased the ADCC efficacy of rituximab in the treatment of the human CD20 expressing murine EL4 leukemia model. IL-15 also augmented efficacy of the combination of anti-CTLA-4 and anti-PD-L1 anti-checkpoint antibodies. These studies support the use of IL-15 in combination with anticancer monoclonal antibodies.